Oral
T-DXd
JSMO 2026 | March 26-28, 2026
A health-related quality-of-life analysis from ERICA study (WJOG14320B)
This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Mini-Oral
Pipeline Compounds
JSMO 2026 | March 26-28, 2026
DS-3939, a TA-MUC1 antibody–drug conjugate in advanced/metastatic solid tumors: Initial first-in-human results
Oral
T-DXd
JSMO 2026 | March 26-28, 2026
Effectiveness of T-DXd rechallenge for HER2+ metastatic breast cancer: The EN-SEMBLE nationwide cohort study
Oral
HER3-DXd
JSMO 2026 | March 26-28, 2026
HERTHENA-PanTumor01: Expansion of a global phase 2 trial of HER3-DXd in patients with advanced/metastatic solid tumors
Oral
I-DXd
JSMO 2026 | March 26-28, 2026
Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer: Japanese subgroup analysis from IDeate-Lung01
Oral
T-DXd
JSMO 2026 | March 26-28, 2026
Intensive versus less-intensive treatment regimens in HER2-positive gastric cancer patients: A database analysis
Poster
R-DXd
JSMO 2026 | March 26-28, 2026
REJOICE-Ovarian01: Phase 2 dose-optimization subgroup analysis – R-DXd in Asian patients with platinum-resistant ovarian cancer
Poster
R-DXd
JSMO 2026 | March 26-28, 2026
REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan
(R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors